Please assess the completion status of the following clinical trial:

Trial Title: Effects of Rosiglitazone and Alpha-lipoic Acid on the Patients With Pathologically Proved NASH

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* the patients with pathologically proved NASH (non-alcoholic steato-hepatitis)~Exclusion Criteria:~* alcohol consumption \> 20g/day~* viral hepatitis B and C~* autoimmune hepatitis~* Wilson's disease~* hemochromatosis~* alpha-1 antitrypsin deficiency~* breast-feeding or pregnant females~* subjects planning to become pregnant~* severe comorbid medical conditions (such as severe cardiac, pulmonary, renal or psychological problems)~* those not consenting for the study

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Control (Type: NO_INTERVENTION): None
- Rosiglitazone (Type: EXPERIMENTAL): Rosiglitazone (8 mg/day)
- alpha-lipoic acid (Type: EXPERIMENTAL): alpha-lipoic acid (1800 mg/day)
- Rosiglitazone/alpha-lipoic acid (Type: EXPERIMENTAL): combination of Rosiglitazone (8 mg/day) and alpha-lipoic acid (1800 mg/day)

Based on this trial design, predict the completion outcome and termination type (if applicable).